QQQ   292.12 (-1.40%)
AAPL   143.31 (-1.80%)
MSFT   243.50 (-1.88%)
META   148.60 (-2.07%)
GOOGL   97.60 (-1.78%)
AMZN   100.91 (-1.30%)
TSLA   171.77 (-3.45%)
NVDA   195.22 (-4.14%)
NIO   12.06 (-5.11%)
BABA   112.07 (-5.33%)
AMD   73.18 (-2.94%)
T   20.11 (+0.80%)
MU   62.15 (-2.69%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.54 (-2.03%)
DIS   108.49 (-0.96%)
AMC   5.00 (-9.26%)
PFE   43.58 (-0.48%)
PYPL   80.79 (-1.27%)
NFLX   356.68 (-1.13%)
QQQ   292.12 (-1.40%)
AAPL   143.31 (-1.80%)
MSFT   243.50 (-1.88%)
META   148.60 (-2.07%)
GOOGL   97.60 (-1.78%)
AMZN   100.91 (-1.30%)
TSLA   171.77 (-3.45%)
NVDA   195.22 (-4.14%)
NIO   12.06 (-5.11%)
BABA   112.07 (-5.33%)
AMD   73.18 (-2.94%)
T   20.11 (+0.80%)
MU   62.15 (-2.69%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.54 (-2.03%)
DIS   108.49 (-0.96%)
AMC   5.00 (-9.26%)
PFE   43.58 (-0.48%)
PYPL   80.79 (-1.27%)
NFLX   356.68 (-1.13%)
QQQ   292.12 (-1.40%)
AAPL   143.31 (-1.80%)
MSFT   243.50 (-1.88%)
META   148.60 (-2.07%)
GOOGL   97.60 (-1.78%)
AMZN   100.91 (-1.30%)
TSLA   171.77 (-3.45%)
NVDA   195.22 (-4.14%)
NIO   12.06 (-5.11%)
BABA   112.07 (-5.33%)
AMD   73.18 (-2.94%)
T   20.11 (+0.80%)
MU   62.15 (-2.69%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.54 (-2.03%)
DIS   108.49 (-0.96%)
AMC   5.00 (-9.26%)
PFE   43.58 (-0.48%)
PYPL   80.79 (-1.27%)
NFLX   356.68 (-1.13%)
QQQ   292.12 (-1.40%)
AAPL   143.31 (-1.80%)
MSFT   243.50 (-1.88%)
META   148.60 (-2.07%)
GOOGL   97.60 (-1.78%)
AMZN   100.91 (-1.30%)
TSLA   171.77 (-3.45%)
NVDA   195.22 (-4.14%)
NIO   12.06 (-5.11%)
BABA   112.07 (-5.33%)
AMD   73.18 (-2.94%)
T   20.11 (+0.80%)
MU   62.15 (-2.69%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.54 (-2.03%)
DIS   108.49 (-0.96%)
AMC   5.00 (-9.26%)
PFE   43.58 (-0.48%)
PYPL   80.79 (-1.27%)
NFLX   356.68 (-1.13%)
NASDAQ:KZR

Kezar Life Sciences - KZR Stock Forecast, Price & News

$6.81
-0.09 (-1.30%)
(As of 01/30/2023 01:51 PM ET)
Add
Compare
Today's Range
$6.69
▼
$6.95
50-Day Range
$6.02
▼
$7.81
52-Week Range
$4.30
▼
$18.55
Volume
120,340 shs
Average Volume
650,271 shs
Market Capitalization
$465.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
169.2% Upside
$18.33 Price Target
Short Interest
Healthy
5.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.51mentions of Kezar Life Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.03) to ($1.17) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

303rd out of 1,049 stocks

Pharmaceutical Preparations Industry

141st out of 514 stocks

See Top Rated MarketRank™ Stocks Here

KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

January 28, 2023 | americanbankingnews.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Morningside Venture Investment Sells 50,000 Shares
January 26, 2023 | americanbankingnews.com
Morningside Venture Investment Sells 80,000 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) Stock
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 20, 2023 | americanbankingnews.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Morningside Venture Investment Sells 6,114 Shares of Stock
January 20, 2023 | americanbankingnews.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Sells $33,850.00 in Stock
January 4, 2023 | finance.yahoo.com
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 | markets.businessinsider.com
Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
November 16, 2022 | seekingalpha.com
Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 14, 2022 | finance.yahoo.com
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 10, 2022 | finance.yahoo.com
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 3, 2022 | finance.yahoo.com
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
October 14, 2022 | finance.yahoo.com
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
October 4, 2022 | forbes.com
Kezar Life Sciences
October 3, 2022 | msn.com
Why Kezar Life Sciences Shares Are Volatile After Hours
October 3, 2022 | finance.yahoo.com
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
September 29, 2022 | finance.yahoo.com
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
September 20, 2022 | nasdaq.com
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt In A Risky Way?
September 1, 2022 | finance.yahoo.com
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
August 30, 2022 | finance.yahoo.com
A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year
August 11, 2022 | finance.yahoo.com
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
July 27, 2022 | seekingalpha.com
Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
July 18, 2022 | finance.yahoo.com
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?
July 11, 2022 | finance.yahoo.com
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 8, 2022 | finance.yahoo.com
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
July 7, 2022 | finance.yahoo.com
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
June 28, 2022 | finance.yahoo.com
Wells Fargo Beefs Up Kezar Life Price Target - Read Why
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings
11/10/2022
Today
1/30/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
CUSIP
N/A
CIK
1645666
Web
www.kezarlifesciences.com
Phone
(650) 822-5600
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+169.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-25.46%
Return on Assets
-23.54%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
31.15
Quick Ratio
31.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.01 per share
Price / Book
1.70

Miscellaneous

Outstanding Shares
68,380,000
Free Float
63,045,000
Market Cap
$465.67 million
Optionable
Not Optionable
Beta
0.23

Key Executives

  • John Fowler
    Chief Executive Officer & Director
  • Christopher J. Kirk
    President, Director & Chief Scientific Officer
  • Michael Wolfe
    Director-Finance & Business Operations
  • Marc L. BelskyMarc L. Belsky
    Chief Financial Officer & Secretary
  • Noreen Roth Henig
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KZR shares.
View KZR analyst ratings or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Kezar Life Sciences' shares. Their KZR share price forecasts range from $14.00 to $21.00. On average, they predict the company's stock price to reach $18.33 in the next twelve months. This suggests a possible upside of 166.1% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2023?

Kezar Life Sciences' stock was trading at $7.04 at the beginning of 2023. Since then, KZR stock has decreased by 2.1% and is now trading at $6.89.
View the best growth stocks for 2023 here.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a drop in short interest in January. As of January 15th, there was short interest totaling 3,870,000 shares, a drop of 37.0% from the December 31st total of 6,140,000 shares. Based on an average daily volume of 646,800 shares, the days-to-cover ratio is presently 6.0 days.
View Kezar Life Sciences' Short Interest.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our KZR earnings forecast.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings data on Thursday, November, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $6.89.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $471.14 million. The company earns $-54,630,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 1/30/2023 by MarketBeat.com Staff